Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]
- Author(s)
- Wu, YL; Majem, M; John, T; Grohé, C; Wang, J; Goldman, JW; Lu, S; Shepherd, FA; Wang, Q; Kato, T; Aokage, K; Zhong, WZ; Laktionov, K; Wu, MF; Akewanlop, C; Vu, HV; Lee, KH; Huang, X; Armenteros-Monterroso, E; Rukazenkov, Y; Herbst, RS;
- Journal Title
- Journal of Thoracic Oncology
- Publication Type
- Online publication before print
- Abstract
- INTRODUCTION: In ADAURA, adjuvant osimertinib improved DFS and OS versus placebo in resected EGFR-mutated stage IB-IIIA NSCLC. We report a post hoc exploratory analysis of long-term OS post-adjuvant treatment completion. METHODS: Patients (N = 682) were randomized to osimertinib or placebo until recurrence, treatment completion, or discontinuation. Updated survival data were collected from 431/558 patients alive at the planned final OS analysis (DCO, 27 January 2023) through yearly follow-up until the current DCO (4 May 2026) or from accessible records/information from last contact date after 27 January 2023. Patients without additional follow-up remained censored, survival time unchanged from the planned final OS analysis DCO (n = 127). This exploratory long-term OS analysis was conducted in all randomized patients. RESULTS: At the current DCO, in the stage II-IIIA population: OS HR was 0.53 (95% CI: 0.38-0.75); 8-year OS rates were 74% (osimertinib) versus 58% (placebo); median follow-up was 92.0 versus 68.5 months. In the stage IB-IIIA population: OS HR was 0.52 (95% CI: 0.39-0.71); 8-year OS rates were 79% (osimertinib) versus 64% (placebo); median follow-up was 93.3 versus 79.6 months. OS HRs according to EGFR Ex19del and L858R mutations were 0.45 (95% CI: 0.29-0.68) and 0.72 (95% CI: 0.46-1.11), respectively. OS benefit with osimertinib was observed across subgroups. CONCLUSIONS: With the longest OS from a global phase III adjuvant trial in EGFR-mutated stage IB-IIIA NSCLC, these additional long-term results further characterize the established survival benefit of adjuvant osimertinib. CLINICAL TRIAL INFORMATION: ADAURA (NCT02511106).
- Keywords
- 8-year overall survival; EGFR mutation; Non-small cell lung cancer; adjuvant therapy; osimertinib
- Department(s)
- Medical Oncology; Haematology
- Publisher's Version
- https://doi.org/10.1016/j.jtho.2026.104179
- Open Access at Publisher's Site
https://doi.org/10.1016/j.jtho.2026.104179- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-10-12 05:40:53
Last Modified: 2026-10-12 05:41:16